We believe conquering cancer is a big data problem. That's why we built the world's leading comprehensive liquid biopsy. This non-invasive tool for accessing & sequencing tumor DNA is used by thousands of oncologists to help tens of thousands of advanced cancer patients. We believe the boom in cancer data acquisition we helped launch will drive important discoveries & new products. We're working on some exciting ones, including in early detection, where the impact on patients can be profound. We've raised more than $500 million from investors including Sequoia Capital, Khosla Ventures, OrbiMed, & SoftBank.
To enable Guardant Health to lead the disruption of cancer treatments through non-invasive cancer screening, the Technology Development Team is seeking a highly motivatedScientist I-II to help test & validate novel technologies for early detection & MRD with next-generation sequencing in a regulated environment.
At Guardant, we leverage the most advanced technologies & work with leaders in many different fields to create the most impactful & meaningful technologies for cancer management.
As a Scientist I-II in the Technology Development Team, you will work with members within the team & interface with multiple teams including process engineering, clinical operations, research operations, & bioinformatics. You will be hands on in the lab & be required to design, implement, & validate new technologies related to liquid biopsy sequencing assays for the early detection, treatment, & monitoring of all cancer types.
Essential Duties & Responsibilities: Be able to work in a team environment & independently to develop, test & validate technologies for NGS-based oncology diagnostics. Think creatively & apply knowledge to design experiments & analyze NGS data for applications in oncology diagnostics. Document product development requirements & validation results. Be highly committed & deliver results in a fast-paced, rigorous environment. Teach & mentor junior team members.